Novartis (Bangladesh) Limited holds 45th Annual General Meeting
Novartis (Bangladesh) Limited declared 20 percent Cash Dividend for the year 2017.
Dhaka, August 12, 2018: The 45th Annual General Meeting (AGM) of Novartis (Bangladesh) Limited, the leading multinational pharmaceutical of the country, was held at Le Meridien Dhaka on Saturday, August 11, 2018.
Mr. Shah Md. Aminul Haq, Chairman, Novartis (Bangladesh) Limited, presided over the meeting.
Dr. Riad Mamun Prodhani, Managing Director, Mr. Sazzad Rahim Chowdhury, Finance Director & Company Secretary, Sheikh Nahar Mahmud, immediate past Managing Director of Novartis (Bangladesh) Limited and Mr. Lutfor Rahman, Director, Finance, Mr. Haiul Quaaium, Director, Commercial of Bangladesh Chemical Industries Corporation (BCIC) attended the AGM along with other high officials of both the organizations. The Shareholders unanimously approved the Financial Statements for the year ended 31 December 2017, Directors’ Report and the Auditor’s Report.
The company declared 20 percent Cash Dividend for the year 2017.
The Board of Directors appreciated the performance of the employees whose persistent efforts helped the Company maintain its Quality leadership in Bangladesh. The Directors also expressed their gratitude and acknowledged the support and cooperation received from its stakeholders including Bangladesh Investment Development Authority (BIDA), National Board of Revenue and other agencies of the public and private sector.
About Novartis (Bangladesh) Ltd.
Novartis (Bangladesh) Limited operates as a subsidiary of Novartis AG, a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. Novartis (Bangladesh) Limited is a joint venture between Novartis AG (60%) and Bangladesh Chemical Industries Corporation (40%) of Government of People's Republic of Bangladesh. The company provides healthcare solutions specializing in research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Novartis operates businesses with global scale and strong customer ties, focusing on innovative patented medicines, generics and eye care devices. The Company exports its products to more than 55 countries in Europe, Asia, Africa and Latin America.